PMID- 25634607
OWN - NLM
STAT- MEDLINE
DCOM- 20160621
LR  - 20211203
IS  - 1776-260X (Electronic)
IS  - 1776-2596 (Linking)
VI  - 10
IP  - 3
DP  - 2015 Sep
TI  - The route to personalized medicine in bladder cancer: where do we stand?
PG  - 325-36
LID - 10.1007/s11523-015-0357-x [doi]
AB  - Recent advances in molecular biology and drug design have described novel targets 
      in bladder cancer. EGFR, fibroblast growth factor receptor (FGFR), VEGFR, 
      phosphoinositide 3-kinase (PI3K)/AKT/mammalian target of rapamycin (mTOR) 
      pathway, PD-1, cyclooxygenase 2 (COX-2), Aurora kinase A, and miRNA are just 
      examples of these opening frontiers. In addition, epithelial to mesenchymal 
      transition (EMT) and cancer stem cells (CSCs) are promising candidates for future 
      therapeutic approaches. Novel agents, combination, and sequences are emerging 
      from the 747 clinical studies presently in course in bladder cancer to optimize 
      patient outcomes. This report describes the emerging targets and provides an 
      update on ongoing phase I, II, and III trials and preliminary results on targeted 
      agents, used alone, in sequences, or in combination for patients with bladder 
      cancer.
FAU - Massari, Francesco
AU  - Massari F
AD  - Medical Oncology, Azienda Ospedaliera Universitaria Integrata, University of 
      Verona, Verona, Italy.
FAU - Ciccarese, Chiara
AU  - Ciccarese C
FAU - Santoni, Matteo
AU  - Santoni M
FAU - Brunelli, Matteo
AU  - Brunelli M
FAU - Conti, Alessandro
AU  - Conti A
FAU - Modena, Alessandra
AU  - Modena A
FAU - Montironi, Rodolfo
AU  - Montironi R
FAU - Santini, Daniele
AU  - Santini D
FAU - Cheng, Liang
AU  - Cheng L
FAU - Martignoni, Guido
AU  - Martignoni G
FAU - Cascinu, Stefano
AU  - Cascinu S
FAU - Tortora, Giampaolo
AU  - Tortora G
LA  - eng
PT  - Journal Article
PT  - Research Support, Non-U.S. Gov't
PT  - Review
DEP - 20150130
PL  - France
TA  - Target Oncol
JT  - Targeted oncology
JID - 101270595
RN  - 0 (Angiopoietins)
RN  - 0 (PDCD1 protein, human)
RN  - 0 (Programmed Cell Death 1 Receptor)
RN  - EC 1.14.99.1 (Cyclooxygenase 2)
RN  - EC 1.14.99.1 (PTGS2 protein, human)
RN  - EC 2.7.1.1 (MTOR protein, human)
RN  - EC 2.7.10.1 (EGFR protein, human)
RN  - EC 2.7.10.1 (ErbB Receptors)
RN  - EC 2.7.10.1 (Vascular Endothelial Growth Factor Receptor-1)
RN  - EC 2.7.11.1 (AURKA protein, human)
RN  - EC 2.7.11.1 (Aurora Kinase A)
RN  - EC 2.7.11.1 (TOR Serine-Threonine Kinases)
SB  - IM
MH  - Angiopoietins/metabolism
MH  - Aurora Kinase A/metabolism
MH  - Carcinogenesis
MH  - Clinical Trials as Topic
MH  - Cyclooxygenase 2/metabolism
MH  - Epithelial-Mesenchymal Transition
MH  - ErbB Receptors/genetics
MH  - Humans
MH  - Neoplastic Stem Cells/cytology
MH  - Precision Medicine/*methods
MH  - Programmed Cell Death 1 Receptor/metabolism
MH  - TOR Serine-Threonine Kinases/metabolism
MH  - Treatment Outcome
MH  - Urinary Bladder Neoplasms/*drug therapy/genetics/pathology
MH  - Vascular Endothelial Growth Factor Receptor-1/genetics
EDAT- 2015/01/31 06:00
MHDA- 2016/06/22 06:00
CRDT- 2015/01/31 06:00
PHST- 2014/12/22 00:00 [received]
PHST- 2015/01/12 00:00 [accepted]
PHST- 2015/01/31 06:00 [entrez]
PHST- 2015/01/31 06:00 [pubmed]
PHST- 2016/06/22 06:00 [medline]
AID - 10.1007/s11523-015-0357-x [doi]
PST - ppublish
SO  - Target Oncol. 2015 Sep;10(3):325-36. doi: 10.1007/s11523-015-0357-x. Epub 2015 
      Jan 30.